Cariprazine for the Treatment of Bipolar Disorder

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial

(2014) Suresh Durgam et al.   BIPOLAR DISORDERS

Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach

(2014) Martin Johnson et al.   PHARMACEUTICAL RESEARCH

Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method

(2014) S. Leucht et al.   SCHIZOPHRENIA BULLETIN

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

(2014) Suresh Durgam et al.   SCHIZOPHRENIA RESEARCH

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

(2013) Leslie Citrome   ADVANCES IN THERAPY

A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach

(2013) Leslie Citrome   CNS DRUGS

Newer antipsychotics and upcoming molecules for schizophrenia

(2013) Melvin George et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial

(2013) J.A. Lieberman et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

(2013) Leslie Citrome   Expert Opinion on Drug Metabolism & Toxicology

History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia

(2013) Bertha K. Madras   Journal of the History of the Neurosciences

Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

(2013) Gerhard Gross et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia

(2013) Silvio Caccia et al.   Therapeutics and Clinical Risk Management

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

(2012) Éva Ágai-Csongor et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

(2012) Ross Zimnisky et al.   PSYCHOPHARMACOLOGY

Receptor targets for antidepressant therapy in bipolar disorder: An overview

(2011) Konstantinos N. Fountoulakis et al.   JOURNAL OF AFFECTIVE DISORDERS

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients

(2009) S. Potkin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression

(2009) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

P.3.c.051 Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers

(2008) M. Kapás et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Sensitive LC–MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine

(2007) Gabriella Pásztor Mészáros et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS